Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | DOT1L | Q8TEK3 | 3/20 | 0.35 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.33 |
| ▸ | POLRMT | O00411 | 1/20 | 0.33 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.30 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.30 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4970560 | 0.88 | CYP2A6 (0.39) | CYP2A6DOT1LMAP4K4POLRMTACVRL1 | |
| SCHEMBL19343962 | 0.88 | CYP2A6 (0.39) | CYP2A6DOT1LMAP4K4POLRMTACVRL1 | |
| SCHEMBL18667150 | 0.88 | CYP2A6 (0.39) | CYP2A6DOT1LMAP4K4POLRMTACVRL1 | |
| SCHEMBL19344220 | 0.88 | CYP2A6 (0.39) | CYP2A6DOT1LMAP4K4POLRMTACVRL1 | |
| SCHEMBL24058306 | 0.86 | POLRMT (0.35) | DOT1LMAP4K4POLRMTTNIK | |
| SCHEMBL20834955 | 0.85 | DOT1L (0.35) | CYP2A6DOT1LMAP4K4POLRMTACVRL1 | |
| SCHEMBL23584543 | 0.83 | MAP4K4 (0.36) | DOT1LMAP4K4POLRMTPIK3CD | |
| SCHEMBL24606280 | 0.83 | DOT1L (0.35) | DOT1LPOLRMT | |
| SCHEMBL24606310 | 0.82 | DOT1L (0.36) | DOT1LPOLRMTPIK3CD | |
| SCHEMBL26237796 | 0.82 | CSNK2A2 (0.35) | DOT1LMAP4K4POLRMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3426664-B1 | SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-06-30 | — | — | EP | disclosed |
| WO-2017153186-A1 | SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-09-14 | — | — | WO | disclosed |